Breakthrough Injectable HIV-Prevention Drug Proves Effective, but Costly
Lenacapavir (Sunlenca), administered every 26 weeks alongside daily antiretroviral therapy (ART), showed comparable HIV suppression. At week 54, viral suppression to fewer than 50 copies/mL was achieved in 85-90% of participants across three groups receiving lenacapavir, whether orally or subcutaneously every 26 weeks, combined with two daily oral ART drugs for the first 28 weeks, […]
Breakthrough Injectable HIV-Prevention Drug Proves Effective, but Costly Read More »